Recursion’s Incoming CEO Needs To Prove That AI Drug Development Can Pay Off

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week.

Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock

Recursion Pharmaceuticals (NASDAQ: RXRX) has been a pioneer in using artificial intelligence (AI) to improve the drug ...
pharmaphorum

Recursion, Exscientia, and AI drug discovery’s moment of truth

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
pharmaphorum

AI biotechs Exscientia and Recursion agree $688m merger

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
TechAnnouncer

Is HackerRank Free? Unpacking the Cost of Coding Challenges

HackerRank offers a good amount of free coding challenges and practice problems for individuals looking to hone their skills. While basic access is free, HackerRank has premium features and ...